Select publications

Ghielmini M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23. Abstract

Hainsworth JD et al. Rituximab as first-line and maintenance therapy for patients with indolent non- Hodgkin’s lymphoma. J Clin Oncol 2002;20(20):4261-7. Abstract

Hieke K et al. Cost evaluation of rituximab plus MCP vs MCP alone in advanced stage indolent non- Hodgkin’s-lymphoma based on a randomized controlled multicenter trial. Proc ASH 2004;Abstract 87.

Van Oers MHJ et al. Chimeric anti-CD20 monoclonal antibody (rituximab; MabThera) in remission induction and maintenance treatment of relapsed /resistant follicular non-Hodgkin’s lymphoma: A Phase III randomized Intergroup clinical trial. Proc ASH 2004;Abstract 586.

Omer N et al. Id/KLH vaccine (FavId™) following treatment with rituximab: An analysis of response rate improvement (RRI) and time-to-progression (TTP) in follicular lymphoma (FL). Proc ASH 2004;Abstract 587.